Evidence map›Paper›PMID 41117183›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

A Novel Zinc(II) Complex for Sonodynamic Therapy Induces Pyroptosis of Breast Cancer Cells and Enhances Anti-Tumor Immune Response.

Sijie Wen, Dongsheng Tang, Lingpu Zhang, Hanchen Zhang, Zheng Cao, Kong Wai Tan, Xiaojun Wang, Haihua Xiao, Kun Shang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sijie WenBeijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
Dongsheng TangBeijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
Lingpu ZhangBeijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
Hanchen ZhangBeijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
Zheng CaoDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA, 90095, USA.
Kong Wai TanDepartment of Chemistry, Faculty of Science, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.
Xiaojun WangDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, P. R. China.
Haihua XiaoBeijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.ORCID https://orcid.org/0000-0001-8159-8187
Kun ShangDepartment of Nuclear Medicine, Peking University People's Hospital, Beijing, 100044, P. R. China.ORCID https://orcid.org/0009-0002-0013-5215

Funding

National Key Research & Development Program 2022YFC2603900National Natural Science Foundation of China 22175189National Natural Science Foundation of China U24A202246
6 · The paper itself

Abstract

Zinc(II) complexes have emerged as promising antitumor agents due to their favorable biosafety and biocompatibility, and demonstrated effectiveness in photodynamic therapy (PDT). However, their therapeutic potential is limited by the poor tissue penetration of PDT agents. Herein, a novel zinc(II) complex designed for sonodynamic therapy (SDT), capable of producing substantial amounts of singlet oxygen upon ultrasonic activation, is introduced. This sonosensitizer effectively induces pyroptosis in breast cancer cells, significantly promoting the antitumor immune response. This work represents the first exploration of zinc(II) complexes in SDT, establishing a new avenue for enhanced therapeutic outcomes against breast cancer.

Indexed as

Antineoplastic AgentsBreast NeoplasmsPyroptosisUltrasonic TherapyZincAnimalsCell Line, TumorFemaleHumansMicePhotochemotherapyAntineoplastic AgentsZincbreast cancerpyroptosissonodynamic therapyzinc(II) complex

Identifiers

PMID41117183
PMCPMC12713055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.